LEXINGTON, Mass.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has expanded its Phase 2 clinical trial of Oncophage® (vitespen) to include NewYork-Presbyterian Hospital/Columbia University Medical Center.
